Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pyxis Oncology (PYXS) Cash & Equivalents (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed Cash & Equivalents for 2 consecutive years, with $15.4 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 20.8% to $15.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.4 million through Dec 2025, down 20.8% year-over-year, with the annual reading at $15.4 million for FY2025, 20.8% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $15.4 million at Pyxis Oncology, up from $8.9 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $28.0 million in Q1 2024, with the low at $8.9 million in Q3 2025.